Mobile

A 24-Week Multicenter, Randomized, Open-Label, Parallel Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients with Moderate-to-Severe Plaque P...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-002649-69

A 24-Week Multicenter, Randomized, Open-Label, Parallel Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients with Moderate-to-Severe Plaque Psoriasis who are Naive to Systemic Treatment

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The coprimary objectives of the study are to test whether ixekizumab Q2W/Q4W is superior to FAE and is superior to MTX at Week 24 in the treatment of patients with moderate-to-severe psoriasis who are candidates for systemic therapy as measured by 75% improvement in Psoriasis Area and Severity Index (PASI 75) from baseline assuming, that non-adherent patients are treatment failures.

Critère d'inclusion

  • Moderate to Severe Plaque Psoriasis

Liens